Approval of COVID-19 test in the UK under CTDA legislation

Paris, France and Camberley, UK – 26 November 2021 – Novacyt (EURONEXTGROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics,announces that, further to the announcement on 2 November 2021, the Company’sgenesig® COVID-19 Real-Time PCR test has been approved in the UK under the UK HealthSecurity Agency’s Medical Devices (Coronavirus Test Device Approvals) (Amendment)Regulations 2021

Visit Page

Validation of COVID-19 tests in the UK under CTDA legislation

Paris, France and Camberley, UK – 2 November 2021 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces an update on the availability of its COVID-19 tests in the UK following implementation of the UK Health Security Agency’s Medical Devices (Coronavirus Test Device Approvals) (Amendment) Regulations 2021 (“CTDA”). http://novacyt.com/wp-content/uploads/2021/11/Novacyt-Validation-of-COVID-19-tests-in-the-UK-under-CTDA-FINAL-ENG.pdf

Visit Page

Results of Annual General Meeting

Paris, France and Camberley, UK – 19 October 2021 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that its Annual General Meeting (AGM), comprising ordinary and extraordinary general meetings, was held yesterday afternoon. The Company is pleased to report that all resolutions proposed to the shareholders were duly passed.

Visit Page